Abstract:
Cancer Therapeutics-related Cardiac Disfunction (CTRCD) is a cardiovascular disease caused by cancer therapies. It is essential to detect CTRCD at an early stage to prolong patients’ lives. However, there aren’t any established screening tests other than ultrasound cardiogram (UCG). For breast cancer patients who are unable to undergo UCG due to surgery wounds or radiation scars in their breasts, Iodine-123 β-methyl-P-iodophenyl-pentadecanoic acid (123I-BMIPP) myocardial scintigraphy will become the preferable second-choice screening test for CTRCD. 123I-BMIPP scintigraphy has been performed in Japan for over 2 decades, however it is not common elsewhere. More than 100 patients were involved in the study, and the results were analyzed with Heart Risk View-S software. Myocardial scintigraphy cannot serve as a perfect alternative to UCG, however, it will become the preferable second-choice screening test, as it could point out the early stage of CTRCD.
Audience Take Away Notes:
- To our knowledge, this is the most extensive research of 123I-BMIPP scintigraphy for CTRCD. The audience will learn how to diagnose CTRCD without using UCG
- This research will benefit the audience who are interested in CTRCD. The guidelines have been established recently by European Society of Cardiology. CTRCD is still a new research field
